Roth Capital affirms Celator Pharmaceuticals (Nasdaq: CPXX) with a Buy rating and $22 price target after the company announced FY15 results earlier.

Analyst Joseph Pantginis noted that Celator posted FY15 EPS of ($0.57), which compares with the firm’s ($0.56) estimate.

Pantginis also commented: With historic data in hand and a significantly de-risked program, in our belief, we now look to the NDA and MAA filings in 3Q16 and 1Q17 respectively. Management has indicated to us that they do not expect the FDA to convene an Advisory Committee. We also believe there is a high likelihood for the company to deliver an ex-U.S. partnership for Vyxeos in the relative near term. We project an upfront payment in the range of $30-50 million and have already modeled a 25% royalty to Celator. Recall the company intends to market the drug in North America on its own. To this end, only a lean salesforce is required (~30 reps) due to the focused nature of AML. With a likely ex-U.S. partner coming, in our belief, the company has extended its cash runway another six months into 2Q17 and is potentially weighing its options for additional cash requirements in order to build out its commercial infrastructure. Vyxeos is a straightforward approach with nothing new for physicians to learn since they are known drugs, so 1) should be easy to adopt and 2) easy to explain to patients (made the old stuff better).

 

Source: Street Insider

Adamas Pharmaceuticals (NASDAQ:ADMS) has tumbled 11.42% during the past week and has dropped 15.34% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 12.61%. Adamas Pharmaceuticals (NASDAQ:ADMS) has underperformed the index by 20.78% in the last 4 weeks. Investors should watch out for further signals and trade with caution. The stock has recorded a 20-day Moving Average of 8.36% and the 50-Day Moving Average is 25.44%.

Adamas Pharmaceuticals (NASDAQ:ADMS) rose 1.77% or 0.22 points on Friday and made its way into the gainers of the day. After trading began at $12.51 the stock was seen hitting $12.765 as a peak level and $12.07 as the lowest level. The stock ended up at $12.64. The daily volume was measured at 487,271 shares. The 52-week high of the share price is $31.84 and the 52-week low is $12.02. The company has a market cap of $271 million. The company shares have dropped 28.79% in the past 52 Weeks. On December 28, 2015 The shares registered one year high of $31.84 and one year low was seen on February 25, 2016 at $12.02. The 50-day moving average is $14.33 and the 200 day moving average is recorded at $17.34. S&P 500 has rallied 2.61% during the last 52-weeks.

Investors should note that the Company has disclosed insider buying and selling activities to the Securities Exchange, The Securities and Exchange Commission has divulged that Lieberburg Ivan M, director of Adamas Pharmaceuticals Inc, had unloaded 3,000 shares at an average price of $16.23 in a transaction dated on December 7, 2015. The total value of the transaction was worth $48,690. Currently the company Insiders own 39.87% of Adamas Pharmaceuticals shares according to the proxy statements. Institutional Investors own 52.23% of Adamas Pharmaceuticals shares. During last six month period, the net percent change held by insiders has seen a change of -15.79%.

Many analysts have stated their opinion on the company shares. Mizuho Securities initiates coverage on Adamas Pharmaceuticals (NASDAQ:ADMS). Mizuho Securities has a Neutral rating on the shares. As per the latest report, the brokerage house announces the price target to $26 per share. The rating by the firm was issued on January 19, 2016.

Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on development and commercialization of therapeutics targeting chronic disorders of central nervous systems (CNS). It is engaged in modifying pharmacokinetic (PK) profiles of approved drugs to create therapeutics for use alone and in fixed-dose combination products. It develops its lead product, ADS-5102 (amantadine hydrochloride), for a complication associated with treatment of Parkinsons disease known as levodopa induced dyskinesia, and as a treatment for one or more additional CNS indications. Its other product candidate is ADS-8704. Through a partnership with Forest Laboratories Holdings Limited, its portfolio includes two drugs commercially available in the United States: Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) and Namenda XR (memantine hydrochloride) extended release and donepezil hydrochloride) and Namenda XR (memantine hydrochloride) extended release capsules.

 

Source: EtH

Vetr upgraded shares of Weight Watchers International, Inc. (NYSE:WTW) from a hold rating to a buy rating in a research report released on Tuesday, MarketBeat Ratings reports. The firm currently has $14.29 target price on the stock.
Several other equities analysts have also weighed in on the stock. Barclays restated a hold rating on shares of Weight Watchers International in a report on Saturday, February 27th. Zacks Investment Research lowered shares of Weight Watchers International from a buy rating to a hold rating in a report on Friday, February 19th. Finally, Craig Hallum increased their price objective on shares of Weight Watchers International from $28.00 to $35.00 and gave the company a buy rating in a report on Monday, December 7th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the company’s stock. Weight Watchers International currently has an average rating of Hold and a consensus price target of $15.38.
Other large investors recently modified their holdings of the company. Smith Asset Management Group LP raised its stake in shares of Weight Watchers International by 640.8% in the fourth quarter. Smith Asset Management Group LP now owns 50,890 shares of the company’s stock worth $1,160,000 after buying an additional 44,020 shares during the last quarter. Paradigm Asset Management Co. LLC bought a new stake in shares of Weight Watchers International during the fourth quarter worth approximately $1,163,000. California State Teachers Retirement System raised its stake in shares of Weight Watchers International by 1.9% in the fourth quarter. California State Teachers Retirement System now owns 51,202 shares of the company’s stock worth $1,167,000 after buying an additional 935 shares during the last quarter. Santa Fe Partners LLC bought a new stake in shares of Weight Watchers International during the fourth quarter worth approximately $1,364,000. Finally, Russell Frank Co bought a new stake in shares of Weight Watchers International during the fourth quarter worth approximately $1,867,000.
Shares of Weight Watchers International (NYSE:WTW) opened at 13.66 on Tuesday. Weight Watchers International has a one year low of $3.67 and a one year high of $28.05. The company has a market capitalization of $869.06 million and a PE ratio of 24.39. The company has a 50-day moving average of $12.83 and a 200-day moving average of $14.92.
Weight Watchers International (NYSE:WTW) last announced its quarterly earnings data on Thursday, February 25th. The company reported ($0.03) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.02 by $0.05. During the same quarter in the prior year, the company earned $0.07 EPS. The company had revenue of $259.20 million for the quarter, compared to analyst estimates of $257.21 million. Weight Watchers International’s revenue for the quarter was down 20.9% compared to the same quarter last year. On average, analysts anticipate that Weight Watchers International will post $0.83 earnings per share for the current year.
Weight Watchers International, Inc is a provider of weight management services. The company operates globally through a network of Company-owned and franchise operations. The Company provides Services and Products including: Weight Management Plans, Clinical Efficacy, and Meetings. Weight Management Plans, provides weight management program comprised of nutritional, exercise and behavioral tools and approaches.

 

Source: Mideast Times

Despite all the market volatility and weakness over the past year, CHTR has held steady in its uptrend and has been consolidating throughout. It was awaiting a heavy volume breakout, but it’s waiting no more. More than 15 million shares changed hands last week as CHTR closed above 200 for the first time ever. Price labels are included on the chart below to highlight the major highs in 2015. The weekly MACD has just made a bullish centerline crossover and shows accelerating price momentum to accompany the heavy volume. Here’s the chart:

 

Source: Stockcharts

On Friday, Shares of Kitov Pharmaceuticals Holdings LTD (NASDAQ:KTOV) surged 27.83% to $4.72. There is no special news release for the company today.

The surge in share price is referred as technical surge.

The company most recent volume stood at 1,281,359 shares as contrast to average volume of 71,034 shares. Over the one year trading period, the stock has a high price of $5.70 and its low price is recorded at $2.20. The company has a market cap of $2.91M.

The year-to-date performance of the company stands at 17.46% with an advance of 16.72% in the last week and -8.42% in the previous three months.

Kitov Pharmaceuticals Holdings LTD (NASDAQ:KTOV) has EPS ratio of -7.94. The stock has a consensus analyst price target of $10 for twelve month.

Kitov Pharmaceuticals Holdings Ltd. engages in developing non-steroidal anti-inflammatory drugs that treat the pain of osteoarthritis without causing cardiovascular problems. It is developing KIT-301 and KIT-302 drugs for the treatment of osteoarthritis. The company was formerly known as Mainrom Line Logistics Ltd. and changed its name to Kitov Pharmaceuticals Holdings Ltd. in August 2013. Kitov Pharmaceuticals Holdings Ltd. is based in Jerusalem, Israel.

Shares of Eclipse Resources Corporation (NYSE:ECR) declined -10.46% to $1.37. There is no special news for the company.

Eclipse Resources Corporation declared the participation of members from the Company’s executive administration team in the following forthcoming shareholder conferences:

Wednesday March 23, 2016 (New Orleans, LA) – Scotia Howard Weil Energy Conference. Benjamin W. Hulburt (Chairman, President and CEO) will present at 10:45 am Central Time and will host one-on-one meetings with Matthew R. DeNezza (Executive Vice President and CFO).
Tuesday April 12, 2016 (New York, NY) – IPAA OGIS Conference. Benjamin W. Hulburt (Chairman, President and CEO) will present at 3:15 pm Eastern Time and will host one-on-one meetings with Matthew R. DeNezza (Executive Vice President and CFO).
On March 2, Eclipse Resources Corporation declared its fourth quarter and full year 2015 financial and operational results, its 2016 Capital Budget, the reaffirmation of its revolving credit facility borrowing base and updated first quarter and full year 2016 guidance.

Revenues for the fourth quarter of 2015 totaled $65.9 million, representing a 31% increase as contrast to revenues for the fourth quarter of 2014. Adjusted Revenue, which includes the impact of cash settled derivatives, and excludes brokered natural gas and marketing revenue, totaled $74.4 million, representing a 41% increase over Adjusted Revenue of $52.6 million in the fourth quarter of 2014. The net loss for the fourth quarter of 2015 was $813.9 million, or $3.66 per share. Adjusted EBITDAX was $31.3 million for the fourth quarter of 2015, or $0.14 per share.

 

Source: Wall Street 24